<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Iran J Psychiatry</journal-id><journal-id journal-id-type="publisher-id">IJPS</journal-id><journal-title-group><journal-title>Iranian Journal of Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">1735-4587</issn><issn pub-type="epub">2008-2215</issn><publisher><publisher-name>Psychiatry &#x00026; Psychology Research Center, Tehran University of Medical Sciences</publisher-name><publisher-loc>Tehran, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29062366</article-id><article-id pub-id-type="pmc">5640576</article-id><article-id pub-id-type="publisher-id">IJPS-12-154</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind Randomized Clinical Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Esalatmanesh</surname><given-names>Sophia</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Biuseh</surname><given-names>Mojtaba</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Noorbala</surname><given-names>Ahmad Ali</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mostafavi</surname><given-names>Seyed-Ali</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rezaei</surname><given-names>Farzin</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mesgarpour</surname><given-names>Bita</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mohammadinejad</surname><given-names>Payam</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Akhondzadeh</surname><given-names>Shahin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>Psychiatry and Psychology Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.</aff><aff id="aff2">
<label>2</label>Psychosomatic Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.</aff><aff id="aff3">
<label>3</label>Qods Hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran.</aff><aff id="aff4">
<label>4</label>National Institute for Medical Research Development (NIMAD), Tehran, Iran.</aff><author-notes><corresp id="cor1"><label>*</label>Corresponding Author: Address: Roozbeh Hospital, South Kargar Avenue, 1333715914, Tehran, Iran. Tel: +98 21 55412222, Fax: +98 21 55419113, <email>Email: s.akhond@neda.net</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2017</year></pub-date><volume>12</volume><issue>3</issue><fpage>154</fpage><lpage>162</lpage><history><date date-type="received"><day>12</day><month>4</month><year>2017</year></date><date date-type="rev-recd"><day>8</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>3</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; Psychiatry &#x00026; Psychology Research Center, Tehran University of Medical Sciences</copyright-statement><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<bold>Objective:</bold> There are different pathophysiological mechanisms for obsessive- compulsive disorder (OCD) as suggested by the serotonergic, dopaminergic, and glutamatergic hypotheses. The present study aimed at comparing the efficacy and safety of saffron (stigma of Crocus sativus) and fluvoxamine in the treatment of mild to moderate obsessive- compulsive disorder.</p><p>
<bold>Method:</bold> In this study, 50 males and females, aged 18 to 60 years, with mild to moderate OCD, participated. The patients were randomly assigned to receive either saffron (30 mg/day, 15 mg twice a day) or fluvoxamine (100 mg/day) for 10 weeks. Using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and the Adverse Event Checklist, we assessed the patients at baseline, and at the second, fourth, sixth, eighth, and tenth week. Finally, the data were analyzed using general linear repeated measures.</p><p>
<bold>Results:</bold> In this study, 46 patients completed the trial. General linear repeated measures demonstrated no significant effect for time-treatment interaction on the Y-BOCS total scores [F (2.42, 106.87) = 0.70, P = 0.52], obsession Y-BOCS subscale scores [F (2.47, 108.87) = 0.77, p = 0.49], and compulsion Y-BOCS subscale scores [F (2.18, 96.06) = 0.25, P = 0.79]. Frequency of adverse events was not significantly different between the 2 groups.</p><p>
<bold>Conclusion:</bold> Our findings suggest that saffron is as effective as fluvoxamine in the treatment of patients with mild to moderate OCD.</p></abstract><kwd-group><title>Key Words</title><kwd><italic>Crocus Sativus</italic></kwd><kwd><italic>OCD</italic></kwd><kwd><italic>Saffron</italic></kwd><kwd><italic>Serotonin</italic></kwd><kwd><italic>Trial</italic></kwd></kwd-group></article-meta></front><body><p>Obsessive-compulsive disorder (OCD) is a common mental disorder with an estimated lifetime prevalence of 1% to 3% in the general population (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Emotional and social capacities and quality of life are severely compromised in OCD patients (<xref rid="B3" ref-type="bibr">3</xref>). Different pathophysiological mechanisms have been suggested for OCD via the serotonergic, dopaminergic, and glutamatergic hypotheses (<xref rid="B4" ref-type="bibr">4</xref>-<xref rid="B7" ref-type="bibr">7</xref>). Several studies have assessed the efficacy of SSRIs for OCD, and the results showed that they are more effective than placebo (<xref rid="B8" ref-type="bibr">8</xref>). </p><p>Exposure and response prevention (ERP) and serotonin reuptake inhibitors (SRIs) are among the first line interventions in the treatment of OCD patients. Even with appropriate treatment, symptoms can wax and wane (<xref rid="B9" ref-type="bibr">9</xref>). High doses of selective serotonin reuptake inhibitors (SSRIs) can cause prolonged QT intervals and arrhythmias (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>Several studies have shown that SSRIs are frequently associated with sexual dysfunction (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). Herbal medications have shown less side effects and drug interactions compared to chemical drugs (<xref rid="B13" ref-type="bibr">13</xref>).</p><p>
<italic>Crocus sativus</italic>, commonly known as saffron, belongs to the Iridaceae family. Saffron contains several compounds such as safranal (responsible for saffron odor and aroma), picrocrocin (responsible for bitter taste of saffron), and crocin (the main saffron antioxidant used as dye material). In folk medicine, saffron is used as an antispasmodic, eupeptic, gingival sedative, anti-catarrhal, nerve-sedative, carminative, diaphoretic, expectorant, stimulant, stomachic, and aphrodisiac (<xref rid="B14" ref-type="bibr">14</xref>). Saffron can affect the chemical neurotransmitters in the brain such as dopamine and glutamate (<xref rid="B15" ref-type="bibr">15</xref>). Previously, we have demonstrated the beneficial antidepressant and antidementia effects of saffron (<xref rid="B16" ref-type="bibr">16</xref>-<xref rid="B20" ref-type="bibr">20</xref>). A recent animal study has reported that active constituents of saffron, crocins, may play a role in compulsive behavior, supporting a functional interaction between crocins and the serotonergic system (<xref rid="B21" ref-type="bibr">21</xref>). To the best of our knowledge, no clinical study was done on the efficacy of saffron in the treatment of OCD. The present study was conducted to assess the efficacy and tolerability of saffron in the treatment of mild to moderate OCD patients compared to fluvoxamine.</p><sec sec-type="materials|methods"><title>Materials and Methods</title><p>
<bold><italic>Trial Setting and Design</italic></bold>
</p><p>This was a single center, 10- week, randomized, double- blind, parallel group trial conducted in the outpatient clinic of Roozbeh psychiatric hospital (affiliated to Tehran University of Medical Sciences, Tehran, Iran) from December 2014 to May 2016. The trial was registered at the Iranian registry of clinical trials (www.irct.ir; registration number: IRCT201407151556N62) prior to the study. The trial protocol was approved by the institutional review board (IRB) of Tehran University of Medical Sciences (Grant No: 25406) and was conducted in accordance with the Declaration of Helsinki and subsequent revisions. All patients signed an informed consent prior to study entry. Patients were informed that they were free to withdraw from the trial at any time without any adverse effect on their therapy or the relationship with their health care provider.</p><p>
<bold><italic>Participants</italic></bold>
</p><p>Males and females aged 18 to 60 years, with a diagnosis of OCD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Test Revision (DSM-V-TR) and a Yale-Brown Obsession Compulsion Scale (Y-BOCS) scores of 12 to 21 (mild to moderate OCD) were eligible to participate in the trial (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). This was the first clinical study to assess the efficacy of saffron in the treatment of OCD patients; and mild to moderate OCD (scores 12 to 21) was selected according to the ethical issues. Exclusion criteria were as follow: any other mental disorder on the DSM- IV axis I, alcohol or substance (other than nicotine or caffeine) dependence, any serious medical illness including cardiac, hepatic, and renal diseases, neurologic diseases, pregnancy, and breast feeding. Participants did not receive any other psychiatric medications 6 weeks prior to the study. <bold><italic>Interventions</italic></bold></p><p>Patients underwent a standard clinical assessment that included a psychiatric evaluation, a structured diagnostic interview, and medical history. Eligible participants were randomized to receive either a capsule of saffron (SaffroMood&#x000ae;, Green Plant Life and containing 15 mg of saffron extract) twice daily, or a fluvoxamine capsule (Sobhan) 100 mg/day for 10 weeks. The stigma extract was standardized based on crocin by means of spectrophotometry. Crocin value is expressed as direct reading of the absorbance at about 440 nm. Each capsule had 1.65&#x02013;1.75 mg crocin. Participants were not allowed to use any psychotropic drug or any behavioral intervention therapy during the course of the trial. </p><p>
<bold><italic>Outcome</italic></bold>
</p><p>Y-BOCS was used to assess patients at baseline and at weeks 2, 4, 6, 8, and 10. Y-BOCS is a validated 10-item rating scale, which has been widely applied in psychiatric studies to measure the severity of OCD symptoms, and has also been used to assess the severity of obsessive and compulsive symptoms in several clinical trials in Iran (<xref rid="B24" ref-type="bibr">24</xref>-<xref rid="B28" ref-type="bibr">28</xref>). Furthermore, Rajezi Esfahani et al. have assessed the reliability and validity of the Persian version of Y-BOCS; and they found that its internal consistency, split-half reliability, and test-retest reliability coefficients varied from 0.89 to 0.99. Moreover, concurrent reliability were evaluated and approved by correlating the Y-BOCS with the SCL-90-R-OCS and SCID-I (<xref rid="B29" ref-type="bibr">29</xref>). The primary outcome measure was the difference in Y-BOCS total score change from baseline to the end of the trial between the 2 groups using the general linear repeated measure model. Secondary outcome measures were comparing changes in Y-BOCS total, obsession and compulsion subscale scores from baseline to week 10 between the 2 groups, partial response rates (&#x02265; 25% reduction in the Y-BOCS score), and complete response rates (&#x02265; 35% reduction in the Y-BOCS score)(<xref rid="B30" ref-type="bibr">30</xref>). Adverse events were recorded systematically at each visit using a checklist (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). All participants were asked about any adverse event, which was not mentioned in the checklist. A thorough physical examination was performed at the screening session and at each postbaseline visit. Furthermore, a complete blood count (CBC) was taken, and serum aminotransferases and renal function test values were measured at baseline and at each postbaseline visit.</p><p>
<bold><italic>Sample Size</italic></bold>
</p><p>A sample size of 46 (each group 23) was calculated assuming a difference of 3 on Y-BOCS, a standard deviation (SD) of 3, a power of 80%, and a two- sided significance level of 5%. Considering a 10% attrition rate, a final sample size of 50 was achieved. </p><p> Randomization, Allocation Concealment, and Blinding</p><p>Generation of randomization codes was conducted by a computerized random number generator (blocks of 4, allocation ratio 1:1) by an independent party, who was not involved elsewhere in the trial. Allocation was concealed using successively numbered, opaque, and sealed envelopes. Saffron and fluvoxamine were identical in their shape, size, texture, color, and odor. The patients, research investigator, and the rater were all blind to the treatment allocation.</p><p>
<bold><italic>Statistical Analysis</italic></bold>
</p><p>Continuous variables were reported as mean &#x000b1; SD, and categorical variables were reported as frequency (percentage). Independent t test was used to compare baseline continuous variables. The mean difference between the saffron and fluvoxamine group was reported as mean difference [MD, 95% confidence interval (CI)]. A general linear model repeated measure was used to evaluate time-treatment interaction considering the treatment groups (saffron vs. fluvoxamine) as the between subject factor, and the study measurement as the within subject factor (time).Whenever Mauchly's test of sphericity was significant; Greenhouse-Geisser adjustment was used for degrees of freedom. An independent t test and Cohen's d effect size were used to compare score change from baseline to each time interval between the 2 groups. Categorical variables were compared using Chi-square or Fisher's exact test where appropriate. All analyses were performed two-sided, and a p-value of less than 0.05 was considered statistically significant. Statistical Package of Social Science Software (SPSS Version 22; IBM Company, USA) was used for statistical analysis. </p></sec><sec sec-type="results"><title>Results</title><p>
<bold><italic>Patients</italic></bold>
</p><p>Among 96 patients, who were screened for the eligibility criteria, 50 patients were entered into the trial and randomized to receive either saffron (n = 25) or fluvoxamine (n = 25). Four patients discontinued the trial (2 patients in each group before Week 2), and a total number of 46 patients (23 in each group) completed the trial (<xref ref-type="fig" rid="F1">Figure1</xref>). Baseline characteristics of the participants are summarized in <xref ref-type="table" rid="T1">Table 1</xref>.</p><p>
<bold><italic>Y-BOCS Total Score</italic></bold>
</p><p>Baseline Y-BOCS total score did not differ significantly between the 2 groups [MD (95% CI) = 0.65 (-1.15 to 2.46), t (44) = 0.72, P = 0.47]. General linear model repeated measures demonstrated no significant effect for time-treatment interaction on Y-BOCS total score during the trial course [F (2.42, 106.87) = 0.70, P = 0.52] (<xref ref-type="fig" rid="F2">Figure 2</xref>). Partial and complete response rates did not differ significantly between the 2 groups at the end of the trial (<xref ref-type="table" rid="T2">Table 2</xref>).</p><table-wrap id="T1" position="float"><label>Table1</label><caption><p>Baseline Characteristics According to the Treatment Group (Saffron and Fluvoxamine)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Saffron </bold>
<break/>
<bold>group(n=23)</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Fluvoxamine </bold>
<break/>
<bold>group(n=23)</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>P-value</bold>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age, years, mean &#x000b1; SD</td><td align="center" valign="middle" rowspan="1" colspan="1">34.00 &#x000b1; 7.14</td><td align="center" valign="middle" rowspan="1" colspan="1">31.22 &#x000b1; 7.27</td><td align="center" valign="middle" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sex, female, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (65.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (56.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">duration of the disease (years), mean &#x000b1; SD</td><td align="center" valign="middle" rowspan="1" colspan="1">10.26 &#x000b1; 5.56</td><td align="center" valign="middle" rowspan="1" colspan="1">9.39 &#x000b1; 5.18</td><td align="center" valign="middle" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Education</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Illiterate</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (21.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1(4.3%)</td><td align="center" valign="middle" rowspan="5" colspan="1">Non significant</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">primary</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (21.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7(30.4%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Middle</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (21.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6(26.1%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">High school</td><td align="center" valign="middle" rowspan="1" colspan="1">4(17.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2(8.7%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Higher</td><td align="center" valign="middle" rowspan="1" colspan="1">4(17.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7(30.4%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Smoking, n, %</td><td align="center" valign="middle" rowspan="1" colspan="1">8(34.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7(30.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Marital status</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Married</td><td align="center" valign="middle" rowspan="1" colspan="1">9(39.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13(56.5%)</td><td align="center" valign="middle" rowspan="3" colspan="1">Non significant</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Single</td><td align="center" valign="middle" rowspan="1" colspan="1">13(56.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7(30.4%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Separated</td><td align="center" valign="middle" rowspan="1" colspan="1">1(4.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3(13%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Y-BOCS total score, mean &#x000b1; SD</td><td align="center" valign="middle" rowspan="1" colspan="1">16.57 &#x000b1; 2.90</td><td align="center" valign="middle" rowspan="1" colspan="1">15.91 &#x000b1; 3.17</td><td align="center" valign="middle" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Y-BOCS obsession subscale, mean &#x000b1; SD</td><td align="center" valign="middle" rowspan="1" colspan="1">9.17 &#x000b1; 2.85</td><td align="center" valign="middle" rowspan="1" colspan="1">9.26 &#x000b1; 3.27</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Y-BOCS compulsion subscale, mean &#x000b1; SD</td><td align="center" valign="middle" rowspan="1" colspan="1">7.39 &#x000b1; 2.10</td><td align="center" valign="middle" rowspan="1" colspan="1">6.65 &#x000b1; 2.70</td><td align="center" valign="middle" rowspan="1" colspan="1">0.30</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float"><label>Table2</label><caption><p>Comparison of Outcome Indexes between the Two Groups (Saffron and Fluvoxamine)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Saffron group</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Fluvoxamine group</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>P-value</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Odd&#x02019;s </bold>
<break/>
<bold>ratio(95%CI)</bold>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Number (%) of partial <break/>response at weak 2</td><td align="center" valign="middle" rowspan="1" colspan="1">3(13%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1(4.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.60</td><td align="center" valign="middle" rowspan="1" colspan="1">3.30(0.31-34.35)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Number (%) of partial <break/>response at weak 4</td><td align="center" valign="middle" rowspan="1" colspan="1">3(13%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4(17.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">0.71(0.14-3.61)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Number (%) of partial <break/>response at weak 6</td><td align="center" valign="middle" rowspan="1" colspan="1">14(60.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6(26.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">4.40(1.26-15.41)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Number (%) of partial <break/>response at weak 8</td><td align="center" valign="middle" rowspan="1" colspan="1">17(73.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">14(60.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.34</td><td align="center" valign="middle" rowspan="1" colspan="1">1.82(0.52-6.37)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Number (%) of partial <break/>response at weak 10</td><td align="center" valign="middle" rowspan="1" colspan="1">16(69.56%)</td><td align="center" valign="middle" rowspan="1" colspan="1">15(65.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">1.92(0.51-7.12)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Number (%) of Complete <break/>response at weak 2</td><td align="center" valign="middle" rowspan="1" colspan="1">0(0%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0(0%)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Number (%) of Complete <break/>response at weak 4</td><td align="center" valign="middle" rowspan="1" colspan="1">3(13%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2(8.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">1.57(0.23-10.43)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Number (%) of Complete <break/>response at weak 6</td><td align="center" valign="middle" rowspan="1" colspan="1">4(17.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4(17.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00(0.21-4.59)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Number (%) of Complete <break/>response at weak 8</td><td align="center" valign="middle" rowspan="1" colspan="1">5(21.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4(17.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">1.31(0.30-5.70)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Number (%) of Complete <break/>response at weak 10</td><td align="center" valign="middle" rowspan="1" colspan="1">8(34.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7(30.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">1.46(0.43-4.98)</td></tr></tbody></table></table-wrap><table-wrap id="T3" position="float"><label>Table3</label><caption><p>Comparison of Changes in the Yale-Brown Obsessive Compulsive Scale Total and Subscales Scores from Baseline between the Two Groups (Saffron and Fluvoxamine) Using Independent T-Test</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Y-BOCS score</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Saffron </bold>
<break/>
<bold>group(n=23)</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Fluvoxamine </bold>
<break/>
<bold>group(n=23)</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Mean difference </bold>
<break/>
<bold>saffron- fluvoxamine </bold>
<break/>
<bold>(95%CI)</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Cohen&#x02019;s d</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>P-value</bold>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">total (weak 2)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.04 &#x000b1; 1.94</td><td align="center" valign="middle" rowspan="1" colspan="1">0.91 &#x000b1; 1.12</td><td align="center" valign="middle" rowspan="1" colspan="1">0.13 ( -0.81 to 1.07)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">total (weak 4)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.39 &#x000b1; 2.48</td><td align="center" valign="middle" rowspan="1" colspan="1">2.04 &#x000b1; 1.63</td><td align="center" valign="middle" rowspan="1" colspan="1">0.34 (-0.90 to 1.59)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.16</td><td align="center" valign="middle" rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">total (weak 6)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.82 &#x000b1; 2.47</td><td align="center" valign="middle" rowspan="1" colspan="1">2.91 &#x000b1; 2.04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.91 (-0.43 to 2.26)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.40</td><td align="center" valign="middle" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">total (weak 8)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.39 &#x000b1; 2.75</td><td align="center" valign="middle" rowspan="1" colspan="1">3.82 &#x000b1; 2.30</td><td align="center" valign="middle" rowspan="1" colspan="1">0.56 (-0.94 to 2.07)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.22</td><td align="center" valign="middle" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">total (weak 10)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.13 &#x000b1; 2.98</td><td align="center" valign="middle" rowspan="1" colspan="1">4.52 &#x000b1; 2.52</td><td align="center" valign="middle" rowspan="1" colspan="1">0.60 (-1.03 to 2.25)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.22</td><td align="center" valign="middle" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">0bsession(weak2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.69 &#x000b1; 1.42</td><td align="center" valign="middle" rowspan="1" colspan="1">0.73 &#x000b1; 0.81</td><td align="center" valign="middle" rowspan="1" colspan="1">-0.04 (-0.73 to 0.64)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" rowspan="1" colspan="1">0.90</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">0bsession(weak4)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.65 &#x000b1; 1.77</td><td align="center" valign="middle" rowspan="1" colspan="1">1.60 &#x000b1; 1.03</td><td align="center" valign="middle" rowspan="1" colspan="1">0.04 (-0.81 to 0.90)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">0bsession(weak6)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.82 &#x000b1; 1.66</td><td align="center" valign="middle" rowspan="1" colspan="1">2.26 &#x000b1; 1.35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.56 (-0.33 to 1.46)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.37</td><td align="center" valign="middle" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">0bsession (weak 8)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.26 &#x000b1; 2.00</td><td align="center" valign="middle" rowspan="1" colspan="1">2.82 &#x000b1; 1.46</td><td align="center" valign="middle" rowspan="1" colspan="1">0.43 (-0.60 to 1.47)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">0bsession (weak 10)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.86 &#x000b1; 2.34</td><td align="center" valign="middle" rowspan="1" colspan="1">3.43 &#x000b1; 1.75</td><td align="center" valign="middle" rowspan="1" colspan="1">0.43 (-0.79 to 1.66)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.20</td><td align="center" valign="middle" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">compulsion (weak 2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.34 &#x000b1; 1.15</td><td align="center" valign="middle" rowspan="1" colspan="1">0.17 &#x000b1; 0.57</td><td align="center" valign="middle" rowspan="1" colspan="1">0.17 (-0.37 to 0.72)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.18</td><td align="center" valign="middle" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">compulsion (weak 4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.69 &#x000b1; 1.49</td><td align="center" valign="middle" rowspan="1" colspan="1">0.43 &#x000b1; 0.84</td><td align="center" valign="middle" rowspan="1" colspan="1">0.26 (-0.45 to 0.98 )</td><td align="center" valign="middle" rowspan="1" colspan="1">0.21</td><td align="center" valign="middle" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">compulsion (weak 6)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.62 &#x000b1;1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.65 &#x000b1; 1.19</td><td align="center" valign="middle" rowspan="1" colspan="1">0.34 (-0.49 to 1.19 )</td><td align="center" valign="middle" rowspan="1" colspan="1">0.24</td><td align="center" valign="middle" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">compulsion (weak 8)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.13 &#x000b1; 1.65</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00 &#x000b1; 1.50</td><td align="center" valign="middle" rowspan="1" colspan="1">0.13 (-0.81 to 1.07)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">compulsion (weak 10)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.26 &#x000b1; 1.62</td><td align="center" valign="middle" rowspan="1" colspan="1">1.08 &#x000b1; 1.62</td><td align="center" valign="middle" rowspan="1" colspan="1">0.17 (-0.79 to 1.13)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.11</td><td align="center" valign="middle" rowspan="1" colspan="1">0.71</td></tr></tbody></table></table-wrap><table-wrap id="T4" position="float"><label>Table4</label><caption><p>The Frequency of Adverse Events in Patients with OCD receiving Saffron or Fluvoxamine</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Adverse event, n, %</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Saffron</bold>
<break/>
<bold>group(n=23)</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Fluvoxamine </bold>
<break/>
<bold>group(n=23)</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>P-value</bold>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">headache, n, %</td><td align="center" valign="middle" rowspan="1" colspan="1">2(8.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3(13%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Dry mouth, n, %</td><td align="center" valign="middle" rowspan="1" colspan="1">3(13%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3(13%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">nausea, n, %</td><td align="center" valign="middle" rowspan="1" colspan="1">3(13%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3(13%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Daytime drowsiness, n, %</td><td align="center" valign="middle" rowspan="1" colspan="1">2(8.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2(8.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">constipation, n, %</td><td align="center" valign="middle" rowspan="1" colspan="1">2(8.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3(13%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">sweating, n, %</td><td align="center" valign="middle" rowspan="1" colspan="1">2(8.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4(17.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">vomiting, n, %</td><td align="center" valign="middle" rowspan="1" colspan="1">2(8.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3(13%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td></tr></tbody></table></table-wrap><fig id="F1" position="float"><label>Figure1</label><caption><p>Flow diagram of the study</p></caption><graphic xlink:href="IJPS-12-154-g001"/></fig><p>
<bold><italic>Y-BOCS Obsession Subscale Score</italic></bold>
</p><p>Baseline Y-BOCS obsession subscale score did not differ significantly between the 2 groups [MD (95% CI) = -0.08 (-1.91 to 1.73), t (44) = -0.09, p = 0.92]. General linear model repeated measure demonstrated no significant effect for time-treatment interaction on Y-BOCS total score [F (2.47, 108.87) = 0.77, p = 0.49] (<xref ref-type="fig" rid="F3">Figure 3</xref>). The reduction in Y-BOCS obsession subscale score did not differ significantly between the 2 groups at weeks 2, 4, 6, 8, and 10 ( <xref ref-type="table" rid="T3">Table 3</xref>(</p><p>
<bold><italic>Y-BOCS Compulsion Subscale Score</italic></bold>
</p><p>Baseline Y-BOCS compulsion subscale scores did not differ significantly between the 2 groups [MD (95% CI) = 0.73 (-0.70 to 2.18), t (44) = 1.03, p = 0.30]. General linear model repeated measure demonstrated no significant effect for time-treatment interaction on Y-BOCS total score [F (2.18, 96.06) = 0.25, P = 0.79] (<xref ref-type="fig" rid="F4">Figure 4</xref>). The reduction in Y-BOCS compulsion subscale score did not differ significantly between the 2 groups at weeks 2, 4, 6, 8, and 10 ( <xref ref-type="table" rid="T3">Table 3</xref>).</p><p>
<bold><italic>Adverse Events</italic></bold>
</p><p>The frequency of adverse events did not differ significantly between treatment groups (<xref ref-type="table" rid="T4">Table 4</xref>). No serious adverse event and no death occurred.</p><fig id="F2" position="float"><label>Figure2</label><caption><p>Repeated measure analysis of variance for the effect of two treatments on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total scores. P-values show the result of the independent t-test for comparison of scores between the two groups at each time interval (mean &#x000b1; SD; NS, not significant).</p></caption><graphic xlink:href="IJPS-12-154-g002"/></fig><fig id="F3" position="float"><label>Figure3</label><caption><p>Repeated measure analysis of variance for the effect of two treatments on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) obsession subscale scores. P-values show the result of the independent t-test for comparison of scores between the two groups at each time interval (mean &#x000b1; SD; NS, not significant).</p></caption><graphic xlink:href="IJPS-12-154-g003"/></fig><fig id="F4" position="float"><label>Figure4</label><caption><p>Repeated measure analysis of variance for the effect of two treatments on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) compulsion subscale scores. P-values show the result of the independent t-test for comparison of scores between the two groups at each time interval (mean &#x000b1; SD; NS, not significant).</p></caption><graphic xlink:href="IJPS-12-154-g004"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>The present study, to the best our knowledge, was the first double- blind study on the efficacy of saffron in the treatment of mild to moderate OCD patients. It provides evidence for satisfactory outcomes with saffron in the treatment of mild to moderate OCD (15 mg, 2 capsules per day). In this double-blind randomized clinical study of <italic>Crocus sativus</italic> stigma vs. fluvoxamine in the treatment of mild to moderate OCD, <italic>Crocus sativus</italic> was demonstrated to be as safe and effective as fluvoxamine for up to 10 weeks after the treatment initiation. Different pathophysiological mechanisms have been considered for OCD including the serotonergic, dopaminergic, and glutamatergic mechanisms (4-6). There is a growing body of evidence suggesting the important role of serotonin (5HT) reuptake inhibitor antidepressants in the treatment of OCD (5). Treatment with clomipramine was reported to reduce the concentration of 5-hydroxyindoleacetic acid (5-HIAA), the major central metabolite of 5HT, in the cerebrospinal fluid (32). In a rat model, a study on the role of striatum in compulsive behavior was conducted and revealed that a primary pathology of the orbitofrontal cortex may lead to dysregulation of the striatal serotonergic system in a subpopulation of OCD patients (33). The serotonergic (5-HT) system plays a major role in the action of antidepressants. Wang et al. reported that <italic>Crocus sativus</italic> corms extract is an effective antidepressant medicinal plant material (34). Previously, we indicated the antidepressant effect of saffron (16, 18 and 35). The antidepressant effects of saffron are potentially due to its serotonergic, antioxidant, anti-inflammatory, neuroendocrine and neuroprotective effects (36). Talaei et al. suggested that the antidepressant effect of saffron extract could be attributed to crocin as the main antioxidant constituent in saffron. In this 4- week trial, addition of crocin tablets (30 mg/day, 15 mg BID) amplified the effects of SSRIs in the treatment of patients with mild to moderate depression (37). Agha-Hosseini et al. indicated the efficacy of saffron in improving depression scores compared to the placebo control group in females with regular menstrual cycles, who experienced premenstrual syndrome (17). Amin et al. reported that crocin and crocetin, 2 major active components of <italic>Crocus sativus</italic>, produced antidepressant-like effect in forced swim test (FST) in mice (38). </p><p>Saffron extract may inhibit serotonin reuptake in synapses. A study on an animal model of obsession compulsion disorder, suggested that crocin may alleviate the mCPP- induced excessive OCD-like behavior (nonselective serotonin (5-HT) receptor agonist) by an antagonist action at the 5-HT2C receptor site and may also support functional interactions between crocins and the serotonergic systems (21). Mohamadpour et al. evaluated the safety of crocin tablets (20 mg per day for 1 month) on biomedical, hormonal, hematological, and urinary parameters in pre- and post-treatment periods. In their study, crocin tablets did not show major side effects or any change in the above- mentioned factors except decreased mixed white blood cells, amylases, and PTT during trial(39). </p></sec><sec><title>Limitations</title><p>Lack of a placebo group, small sample size, and short follow-up period were the limitations of this study. Further research, taking into account the above- mentioned limitations in this realm, is highly recommended.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>The results of the present study revealed that saffron is effective in the treatment of mild to moderate obsessive compulsive disorder. In addition, this study found that saffron does not have any serious adverse effects in 30 mg/day doses and that saffron is both tolerable and effective in the treatment of mild to moderate depression.</p></sec></body><back><ack><title>Acknowledgment</title><p>This study was postgraduate thesis of Dr Mojtaba Biuseh toward the Iranian Board of Psychiatry under supervision of Prof. Shahin Akhondzadeh.</p><p>This study was supported by a grant from Tehran University of Medical Sciences (Grant No: 25406).</p></ack><sec><title>Conflict of interest</title><p>None of the authors contributing to this article have any conflict of interest to report.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasson</surname><given-names>Y</given-names></name><name><surname>Zohar</surname><given-names>J</given-names></name><name><surname>Chopra</surname><given-names>M</given-names></name><name><surname>Lustig</surname><given-names>M</given-names></name><name><surname>Iancu</surname><given-names>I</given-names></name><name><surname>Hendler</surname><given-names>T</given-names></name></person-group><article-title>Epidemiology of obsessive-compulsive disorder: a world view</article-title><source> J Clin Psychiatry</source><year>1997</year><volume>58 Suppl 12</volume><fpage>7</fpage><lpage>10</lpage></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>PH</given-names></name></person-group><article-title>Obsessive-compulsive disorders</article-title><source> Eur Child Adolesc Psychiatry</source><year>2013</year><volume>22 Suppl 1</volume><fpage>S23</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">23208425</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauschildt</surname><given-names>M</given-names></name><name><surname>Moritz</surname><given-names>S</given-names></name></person-group><article-title>[Obsessive-compulsive disorder: psychosocial consequences and quality of life: a review]</article-title><source> Nervenarzt</source><year>2011</year><volume>82</volume><fpage>281</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">21340637</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denys</surname><given-names>D</given-names></name><name><surname>van</surname><given-names>der Wee N</given-names></name><name><surname>Janssen</surname><given-names>J</given-names></name><name><surname>De</surname><given-names>Geus F</given-names></name><name><surname>Westenberg</surname><given-names>HG</given-names></name></person-group><article-title>Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder</article-title><source> Biol Psychiatry</source><year>2004</year><volume>55</volume><fpage>1041</fpage><lpage>1045</lpage><pub-id pub-id-type="pmid">15121489</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aouizerate</surname><given-names>B</given-names></name><name><surname>Guehl</surname><given-names>D</given-names></name><name><surname>Cuny</surname><given-names>E</given-names></name><name><surname>Rougier</surname><given-names>A</given-names></name><name><surname>Burbaud</surname><given-names>P</given-names></name><name><surname>Tignol</surname><given-names>J</given-names></name><etal/></person-group><article-title>Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorder</article-title><source> Neuropsychiatr Dis Treat</source><year>2005</year><volume>1</volume><fpage>231</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">18568072</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pittenger</surname><given-names>C</given-names></name><name><surname>Bloch</surname><given-names>MH</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name></person-group><article-title>Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment</article-title><source> Pharmacol Ther</source><year>2011</year><volume>132</volume><fpage>314</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">21963369</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esalatmanesh</surname><given-names>S</given-names></name><name><surname>Abrishami</surname><given-names>Z</given-names></name><name><surname>Zeinoddini</surname><given-names>A</given-names></name><name><surname>Rahiminejad</surname><given-names>F</given-names></name><name><surname>Sadeghi</surname><given-names>M</given-names></name><name><surname>Najarzadegan</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial</article-title><source> Psychiatry Clin Neurosci</source><year>2016</year><volume>70</volume><fpage>517</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">27488081</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soomro</surname><given-names>GM</given-names></name><name><surname>Altman</surname><given-names>D</given-names></name><name><surname>Rajagopal</surname><given-names>S</given-names></name><name><surname>Oakley-Browne</surname><given-names>M</given-names></name></person-group><article-title>Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).</article-title><source> Cochrane Database Syst Rev</source><year>2008</year><fpage>CD001765</fpage><pub-id pub-id-type="pmid">18253995</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seibell</surname><given-names>PJ</given-names></name><name><surname>Hollander</surname><given-names>E</given-names></name></person-group><article-title>Management of obsessive-compulsive disorder</article-title><source> F1000Prime Rep</source><year>2014</year><volume>6</volume><fpage>68</fpage><pub-id pub-id-type="pmid">25165567</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brakoulias</surname><given-names>V</given-names></name></person-group><article-title>Managing obsessive compulsive disorder</article-title><source> Aust Prescr</source><year>2015</year><volume>38</volume><fpage>121</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">26648639</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kashani</surname><given-names>L</given-names></name><name><surname>Raisi</surname><given-names>F</given-names></name><name><surname>Saroukhani</surname><given-names>S</given-names></name><name><surname>Sohrabi</surname><given-names>H</given-names></name><name><surname>Modabbernia</surname><given-names>A</given-names></name><name><surname>Nasehi</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study</article-title><source> Hum Psychopharmacol</source><year>2013</year><volume>28</volume><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">23280545</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khazaie</surname><given-names>H</given-names></name><name><surname>Rezaie</surname><given-names>L</given-names></name><name><surname>Rezaei</surname><given-names>Payam N</given-names></name><name><surname>Najafi</surname><given-names>F</given-names></name></person-group><article-title>Antidepressant-induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone; a randomized controlled trial</article-title><source> Gen Hosp Psychiatry</source><year>2015</year><volume>37</volume><fpage>40</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">25467077</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmadi</surname><given-names>SM</given-names></name><name><surname>Mohammadi</surname><given-names>MR</given-names></name><name><surname>Mostafavi</surname><given-names>SA</given-names></name><name><surname>Keshavarzi</surname><given-names>S</given-names></name><name><surname>Kooshesh</surname><given-names>SM</given-names></name><name><surname>Joulaei</surname><given-names>H</given-names></name><etal/></person-group><article-title>Dependence of the geriatric depression on nutritional status and anthropometric indices in elderly population</article-title><source> Iran J Psychiatry</source><year>2013</year><volume>8</volume><fpage>92</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">24130608</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kashani</surname><given-names>L</given-names></name><name><surname>Eslatmanesh</surname><given-names>S</given-names></name><name><surname>Saedi</surname><given-names>N</given-names></name><name><surname>Niroomand</surname><given-names>N</given-names></name><name><surname>Ebrahimi</surname><given-names>M</given-names></name><name><surname>Hosseinian</surname><given-names>M</given-names></name><etal/></person-group><article-title>Comparison of Saffron versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial</article-title><source> Pharmacopsychiatry</source><year>2017</year><volume>50</volume><fpage>64</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">27595298</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khazdair</surname><given-names>MR</given-names></name><name><surname>Boskabady</surname><given-names>MH</given-names></name><name><surname>Hosseini</surname><given-names>M</given-names></name><name><surname>Rezaee</surname><given-names>R</given-names></name><name><surname>A</surname><given-names>MT</given-names></name></person-group><article-title>The effects of Crocus sativus (saffron) and its constituents on nervous system: A review</article-title><source> Avicenna J Phytomed</source><year>2015</year><volume>5</volume><fpage>376</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">26468457</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhondzadeh</surname><given-names>S</given-names></name><name><surname>Fallah-Pour</surname><given-names>H</given-names></name><name><surname>Afkham</surname><given-names>K</given-names></name><name><surname>Jamshidi</surname><given-names>AH</given-names></name><name><surname>Khalighi-Cigaroudi</surname><given-names>F</given-names></name></person-group><article-title>Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]</article-title><source> BMC Complement Altern Med</source><year>2004</year><volume>4</volume><fpage>12</fpage><pub-id pub-id-type="pmid">15341662</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agha-Hosseini</surname><given-names>M</given-names></name><name><surname>Kashani</surname><given-names>L</given-names></name><name><surname>Aleyaseen</surname><given-names>A</given-names></name><name><surname>Ghoreishi</surname><given-names>A</given-names></name><name><surname>Rahmanpour</surname><given-names>H</given-names></name><name><surname>Zarrinara</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial</article-title><source> Bjog</source><year>2008</year><volume>115</volume><fpage>515</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">18271889</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahmansouri</surname><given-names>N</given-names></name><name><surname>Farokhnia</surname><given-names>M</given-names></name><name><surname>Abbasi</surname><given-names>SH</given-names></name><name><surname>Kassaian</surname><given-names>SE</given-names></name><name><surname>Noorbala</surname><given-names>Tafti AA</given-names></name><name><surname>Gougol</surname><given-names>A</given-names></name><etal/></person-group><article-title>A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients</article-title><source> J Affect Disord</source><year>2014</year><volume>155</volume><fpage>216</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">24289892</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhondzadeh</surname><given-names>S</given-names></name><name><surname>Sabet</surname><given-names>MS</given-names></name><name><surname>Harirchian</surname><given-names>MH</given-names></name><name><surname>Togha</surname><given-names>M</given-names></name><name><surname>Cheraghmakani</surname><given-names>H</given-names></name><name><surname>Razeghi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial</article-title><source> J Clin Pharm Ther</source><year>2010</year><volume>35</volume><fpage>581</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">20831681</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farokhnia</surname><given-names>M</given-names></name><name><surname>Shafiee</surname><given-names>Sabet M</given-names></name><name><surname>Iranpour</surname><given-names>N</given-names></name><name><surname>Gougol</surname><given-names>A</given-names></name><name><surname>Yekehtaz</surname><given-names>H</given-names></name><name><surname>Alimardani</surname><given-names>R</given-names></name><etal/></person-group><article-title>Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial</article-title><source> Hum Psychopharmacol</source><year>2014</year><volume>29</volume><fpage>351</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">25163440</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgiadou</surname><given-names>G</given-names></name><name><surname>Tarantilis</surname><given-names>PA</given-names></name><name><surname>Pitsikas</surname><given-names>N</given-names></name></person-group><article-title>Effects of the active constituents of Crocus sativus L., crocins, in an animal model of obsessive-compulsive disorder</article-title><source> Neurosci Lett</source><year>2012</year><volume>528</volume><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">22985509</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>WK</given-names></name><name><surname>Price</surname><given-names>LH</given-names></name><name><surname>Rasmussen</surname><given-names>SA</given-names></name><name><surname>Mazure</surname><given-names>C</given-names></name><name><surname>Delgado</surname><given-names>P</given-names></name><name><surname>Heninger</surname><given-names>GR</given-names></name><etal/></person-group><article-title>The Yale-Brown Obsessive Compulsive Scale. II. Validity</article-title><source> Arch Gen Psychiatry</source><year>1989</year><volume>46</volume><fpage>1012</fpage><lpage>1016</lpage><pub-id pub-id-type="pmid">2510699</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>WK</given-names></name><name><surname>Price</surname><given-names>LH</given-names></name><name><surname>Rasmussen</surname><given-names>SA</given-names></name><name><surname>Mazure</surname><given-names>C</given-names></name><name><surname>Fleischmann</surname><given-names>RL</given-names></name><name><surname>Hill</surname><given-names>CL</given-names></name><etal/></person-group><article-title>The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability</article-title><source> Arch Gen Psychiatry</source><year>1989</year><volume>46</volume><fpage>1006</fpage><lpage>1011</lpage><pub-id pub-id-type="pmid">2684084</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidari</surname><given-names>M</given-names></name><name><surname>Zarei</surname><given-names>M</given-names></name><name><surname>Hosseini</surname><given-names>SM</given-names></name><name><surname>Taghvaei</surname><given-names>R</given-names></name><name><surname>Maleki</surname><given-names>H</given-names></name><name><surname>Tabrizi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder</article-title><source> Int Clin Psychopharmacol</source><year>2014</year><volume>29</volume><fpage>344</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">24850229</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shalbafan</surname><given-names>M</given-names></name><name><surname>Mohammadinejad</surname><given-names>P</given-names></name><name><surname>Shariat</surname><given-names>SV</given-names></name><name><surname>Alavi</surname><given-names>K</given-names></name><name><surname>Zeinoddini</surname><given-names>A</given-names></name><name><surname>Salehi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial</article-title><source> Pharmacopsychiatry</source><year>2015</year><volume>48</volume><fpage>136</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">25959196</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emamzadehfard</surname><given-names>S</given-names></name><name><surname>Kamaloo</surname><given-names>A</given-names></name><name><surname>Paydary</surname><given-names>K</given-names></name><name><surname>Ahmadipour</surname><given-names>A</given-names></name><name><surname>Zeinoddini</surname><given-names>A</given-names></name><name><surname>Ghaleiha</surname><given-names>A</given-names></name><etal/></person-group><article-title>Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study</article-title><source> Psychiatry Clin Neurosci</source><year>2016</year><volume>70</volume><fpage>332</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">27106362</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghaleiha</surname><given-names>A</given-names></name><name><surname>Entezari</surname><given-names>N</given-names></name><name><surname>Modabbernia</surname><given-names>A</given-names></name><name><surname>Najand</surname><given-names>B</given-names></name><name><surname>Askari</surname><given-names>N</given-names></name><name><surname>Tabrizi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study</article-title><source> J Psychiatr Res</source><year>2013</year><volume>47</volume><fpage>175</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">23063327</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paydary</surname><given-names>K</given-names></name><name><surname>Akamaloo</surname><given-names>A</given-names></name><name><surname>Ahmadipour</surname><given-names>A</given-names></name><name><surname>Pishgar</surname><given-names>F</given-names></name><name><surname>Emamzadehfard</surname><given-names>S</given-names></name><name><surname>Akhondzadeh</surname><given-names>S</given-names></name></person-group><article-title>N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial</article-title><source> J Clin Pharm Ther</source><year>2016</year><volume>41</volume><fpage>214</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">26931055</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sepideh</surname><given-names>Rajezi Esfahani YM</given-names></name><name><surname>Kambiz</surname><given-names>Kamkari</given-names></name><name><surname>Alireza</surname><given-names>Zahiredin</given-names></name><name><surname>Masuod</surname><given-names>Janbozorgi</given-names></name></person-group><article-title>Reliability and Validity of the Persian Version of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)</article-title><source> IJPCP</source><year>2012</year><volume>17</volume><fpage>297</fpage><lpage>303</lpage></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Askari</surname><given-names>N</given-names></name><name><surname>Moin</surname><given-names>M</given-names></name><name><surname>Sanati</surname><given-names>M</given-names></name><name><surname>Tajdini</surname><given-names>M</given-names></name><name><surname>Hosseini</surname><given-names>SM</given-names></name><name><surname>Modabbernia</surname><given-names>A</given-names></name><etal/></person-group><article-title>Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial</article-title><source> CNS Drugs</source><year>2012</year><volume>26</volume><fpage>883</fpage><lpage>892</lpage><pub-id pub-id-type="pmid">22873680</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhondzadeh</surname><given-names>S</given-names></name><name><surname>Malek-Hosseini</surname><given-names>M</given-names></name><name><surname>Ghoreishi</surname><given-names>A</given-names></name><name><surname>Raznahan</surname><given-names>M</given-names></name><name><surname>Rezazadeh</surname><given-names>SA</given-names></name></person-group><article-title>Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study</article-title><source> Prog Neuropsychopharmacol Biol Psychiatry</source><year>2008</year><volume>32</volume><fpage>1879</fpage><lpage>1883</lpage><pub-id pub-id-type="pmid">18801405</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thoren</surname><given-names>P</given-names></name><name><surname>Asberg</surname><given-names>M</given-names></name><name><surname>Bertilsson</surname><given-names>L</given-names></name><name><surname>Mellstrom</surname><given-names>B</given-names></name><name><surname>Sjoqvist</surname><given-names>F</given-names></name><name><surname>Traskman</surname><given-names>L</given-names></name></person-group><article-title>Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects</article-title><source> Arch Gen Psychiatry</source><year>1980</year><volume>37</volume><fpage>1289</fpage><lpage>1294</lpage><pub-id pub-id-type="pmid">6159865</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schilman</surname><given-names>EA</given-names></name><name><surname>Klavir</surname><given-names>O</given-names></name><name><surname>Winter</surname><given-names>C</given-names></name><name><surname>Sohr</surname><given-names>R</given-names></name><name><surname>Joel</surname><given-names>D</given-names></name></person-group><article-title>The role of the striatum in compulsive behavior in intact and orbitofrontal-cortex-lesioned rats: possible involvement of the serotonergic system</article-title><source> Neuropsychopharmacology</source><year>2010</year><volume>35</volume><fpage>1026</fpage><lpage>1039</lpage><pub-id pub-id-type="pmid">20072118</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>CJ</given-names></name><name><surname>Ming</surname><given-names>QL</given-names></name><name><surname>Rahman</surname><given-names>K</given-names></name><etal/></person-group><article-title>Antidepressant properties of bioactive fractions from the extract of Crocus sativus L</article-title><source> J Nat Med</source><year>2010</year><volume>64</volume><fpage>24</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">19787421</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhondzadeh</surname><given-names>Basti A</given-names></name><name><surname>Moshiri</surname><given-names>E</given-names></name><name><surname>Noorbala</surname><given-names>AA</given-names></name><name><surname>Jamshidi</surname><given-names>AH</given-names></name><name><surname>Abbasi</surname><given-names>SH</given-names></name><name><surname>Akhondzadeh</surname><given-names>S</given-names></name></person-group><article-title>Comparison of petal of Crocus sativus L and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial</article-title><source> Prog Neuropsychopharmacol Biol Psychiatry</source><year>2007</year><volume>31</volume><fpage>439</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">17174460</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopresti</surname><given-names>AL</given-names></name><name><surname>Drummond</surname><given-names>PD</given-names></name></person-group><article-title>Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action</article-title><source> Hum Psychopharmacol</source><year>2014</year><volume>29</volume><fpage>517</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">25384672</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talaei</surname><given-names>A</given-names></name><name><surname>Hassanpour</surname><given-names>Moghadam M</given-names></name><name><surname>Sajadi</surname><given-names>Tabassi SA</given-names></name><name><surname>Mohajeri</surname><given-names>SA</given-names></name></person-group><article-title>Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial</article-title><source> J Affect Disord</source><year>2015</year><volume>174</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">25484177</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname><given-names>B</given-names></name><name><surname>Nakhsaz</surname><given-names>A</given-names></name><name><surname>Hosseinzadeh</surname><given-names>H</given-names></name></person-group><article-title>Evaluation of the antidepressant-like effects of acute and sub-acute administration of crocin and crocetin in mice</article-title><source> Avicenna J Phytomed</source><year>2015</year><volume>5</volume><fpage>458</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">26468466</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohamadpour</surname><given-names>AH</given-names></name><name><surname>Ayati</surname><given-names>Z</given-names></name><name><surname>Parizadeh</surname><given-names>MR</given-names></name><name><surname>Rajbai</surname><given-names>O</given-names></name><name><surname>Hosseinzadeh</surname><given-names>H</given-names></name></person-group><article-title>Safety Evaluation of Crocin (a constituent of saffron) Tablets in Healthy Volunteers</article-title><source> Iran J Basic Med Sci</source><year>2013</year><volume>16</volume><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">23638291</pub-id></element-citation></ref></ref-list></back></article>